RELAPSED AND REFRACTORY MULTIPLE MYELOMA, EVOLUTION AND COMPLICATIONS SINGLE CENTER EXPERIENCE
(Abstract release date: 05/19/16)
EHA Library. Ionita H. 06/09/16; 134886; PB1986
Prof. Hortensia Ionita
Contributions
Contributions
Abstract
Abstract: PB1986
Type: Publication Only
Background
Multiple myeloma (MM) is a malignant plasma cell disorder. It is the second most frequent haematological malignancy and characterized by malignant plasma infiltration or the bone marrow and is associated with an increased level of monoclonal protein in the blood and/or urine. The treatment of MM has undergone significant developments in recent years, and the new agents with potent anti tumor activity has considerably improved the survival of MM patients.
Aims
Retrospective evaluation of the therapeutic results, the evolution and complications of therapy with bortezomib, doxorubicin and dexamethasone (PAD) in the treatment of relapsed/refractory myeloma patients.
Methods
62 patients were treated for median of four 28-day PAD cycles (1-8). Bortezomib was given at 1.3 mg/m2 (days 1, 4, 8,11), doxorubicin at 9 mg/m2 (days 1-4) and dexamethasone 20 mg p.o. (days 1-4, 8-11).
Results
62 patients were evaluable for efficacy, 59% had refractory disease and 41% were relapsed. The median age was 65 years (37-80), 59% were male, 41% female. Serum protein electrophoresis revealed a localized band in 74% of patients, and immunoelectrophoresis or immunofixation showed a monoclonal protein in 85%. A monoclonal light-chain was found in the urine in 63%. Non-secretory myeloma was recognized in 3% of patients, whereas light-chain myeloma was present in 16%. Serum albumin less than 3mg/dl was found in 58% of patients. Conventional radiographs showed an abnormality in 81%. Median time from diagnosis was 16 months (2-115) and median number of prior therapy lines was 2 (1-5).Overall response rate of 58% was observed, 28% of patients achieved a complete response (CR), 22% a very good partial response (VGPR), 30% a partial response (PR). Stable disease (SD) was observed in 20%. The median progression free survival (PFS) was 15,2 months. The most common grade 3-4 toxic effects were neutropenia 14%, thrombocytopenia 12%, anemia 12%, infections 16%, peripheral neuropathy 10% and gastrointestinal disturbances 5%. One toxic death (1.1%) due to sepsis was noted.
Conclusion
The combination of bortezomib, doxorubicin and dexamethasone (PAD) is well tolerated and induced clinically signifiant responses and prolonged remission duration in patients with relapsed and refractory MM.
Session topic: E-poster
Type: Publication Only
Background
Multiple myeloma (MM) is a malignant plasma cell disorder. It is the second most frequent haematological malignancy and characterized by malignant plasma infiltration or the bone marrow and is associated with an increased level of monoclonal protein in the blood and/or urine. The treatment of MM has undergone significant developments in recent years, and the new agents with potent anti tumor activity has considerably improved the survival of MM patients.
Aims
Retrospective evaluation of the therapeutic results, the evolution and complications of therapy with bortezomib, doxorubicin and dexamethasone (PAD) in the treatment of relapsed/refractory myeloma patients.
Methods
62 patients were treated for median of four 28-day PAD cycles (1-8). Bortezomib was given at 1.3 mg/m2 (days 1, 4, 8,11), doxorubicin at 9 mg/m2 (days 1-4) and dexamethasone 20 mg p.o. (days 1-4, 8-11).
Results
62 patients were evaluable for efficacy, 59% had refractory disease and 41% were relapsed. The median age was 65 years (37-80), 59% were male, 41% female. Serum protein electrophoresis revealed a localized band in 74% of patients, and immunoelectrophoresis or immunofixation showed a monoclonal protein in 85%. A monoclonal light-chain was found in the urine in 63%. Non-secretory myeloma was recognized in 3% of patients, whereas light-chain myeloma was present in 16%. Serum albumin less than 3mg/dl was found in 58% of patients. Conventional radiographs showed an abnormality in 81%. Median time from diagnosis was 16 months (2-115) and median number of prior therapy lines was 2 (1-5).Overall response rate of 58% was observed, 28% of patients achieved a complete response (CR), 22% a very good partial response (VGPR), 30% a partial response (PR). Stable disease (SD) was observed in 20%. The median progression free survival (PFS) was 15,2 months. The most common grade 3-4 toxic effects were neutropenia 14%, thrombocytopenia 12%, anemia 12%, infections 16%, peripheral neuropathy 10% and gastrointestinal disturbances 5%. One toxic death (1.1%) due to sepsis was noted.
Conclusion
The combination of bortezomib, doxorubicin and dexamethasone (PAD) is well tolerated and induced clinically signifiant responses and prolonged remission duration in patients with relapsed and refractory MM.
Session topic: E-poster
Abstract: PB1986
Type: Publication Only
Background
Multiple myeloma (MM) is a malignant plasma cell disorder. It is the second most frequent haematological malignancy and characterized by malignant plasma infiltration or the bone marrow and is associated with an increased level of monoclonal protein in the blood and/or urine. The treatment of MM has undergone significant developments in recent years, and the new agents with potent anti tumor activity has considerably improved the survival of MM patients.
Aims
Retrospective evaluation of the therapeutic results, the evolution and complications of therapy with bortezomib, doxorubicin and dexamethasone (PAD) in the treatment of relapsed/refractory myeloma patients.
Methods
62 patients were treated for median of four 28-day PAD cycles (1-8). Bortezomib was given at 1.3 mg/m2 (days 1, 4, 8,11), doxorubicin at 9 mg/m2 (days 1-4) and dexamethasone 20 mg p.o. (days 1-4, 8-11).
Results
62 patients were evaluable for efficacy, 59% had refractory disease and 41% were relapsed. The median age was 65 years (37-80), 59% were male, 41% female. Serum protein electrophoresis revealed a localized band in 74% of patients, and immunoelectrophoresis or immunofixation showed a monoclonal protein in 85%. A monoclonal light-chain was found in the urine in 63%. Non-secretory myeloma was recognized in 3% of patients, whereas light-chain myeloma was present in 16%. Serum albumin less than 3mg/dl was found in 58% of patients. Conventional radiographs showed an abnormality in 81%. Median time from diagnosis was 16 months (2-115) and median number of prior therapy lines was 2 (1-5).Overall response rate of 58% was observed, 28% of patients achieved a complete response (CR), 22% a very good partial response (VGPR), 30% a partial response (PR). Stable disease (SD) was observed in 20%. The median progression free survival (PFS) was 15,2 months. The most common grade 3-4 toxic effects were neutropenia 14%, thrombocytopenia 12%, anemia 12%, infections 16%, peripheral neuropathy 10% and gastrointestinal disturbances 5%. One toxic death (1.1%) due to sepsis was noted.
Conclusion
The combination of bortezomib, doxorubicin and dexamethasone (PAD) is well tolerated and induced clinically signifiant responses and prolonged remission duration in patients with relapsed and refractory MM.
Session topic: E-poster
Type: Publication Only
Background
Multiple myeloma (MM) is a malignant plasma cell disorder. It is the second most frequent haematological malignancy and characterized by malignant plasma infiltration or the bone marrow and is associated with an increased level of monoclonal protein in the blood and/or urine. The treatment of MM has undergone significant developments in recent years, and the new agents with potent anti tumor activity has considerably improved the survival of MM patients.
Aims
Retrospective evaluation of the therapeutic results, the evolution and complications of therapy with bortezomib, doxorubicin and dexamethasone (PAD) in the treatment of relapsed/refractory myeloma patients.
Methods
62 patients were treated for median of four 28-day PAD cycles (1-8). Bortezomib was given at 1.3 mg/m2 (days 1, 4, 8,11), doxorubicin at 9 mg/m2 (days 1-4) and dexamethasone 20 mg p.o. (days 1-4, 8-11).
Results
62 patients were evaluable for efficacy, 59% had refractory disease and 41% were relapsed. The median age was 65 years (37-80), 59% were male, 41% female. Serum protein electrophoresis revealed a localized band in 74% of patients, and immunoelectrophoresis or immunofixation showed a monoclonal protein in 85%. A monoclonal light-chain was found in the urine in 63%. Non-secretory myeloma was recognized in 3% of patients, whereas light-chain myeloma was present in 16%. Serum albumin less than 3mg/dl was found in 58% of patients. Conventional radiographs showed an abnormality in 81%. Median time from diagnosis was 16 months (2-115) and median number of prior therapy lines was 2 (1-5).Overall response rate of 58% was observed, 28% of patients achieved a complete response (CR), 22% a very good partial response (VGPR), 30% a partial response (PR). Stable disease (SD) was observed in 20%. The median progression free survival (PFS) was 15,2 months. The most common grade 3-4 toxic effects were neutropenia 14%, thrombocytopenia 12%, anemia 12%, infections 16%, peripheral neuropathy 10% and gastrointestinal disturbances 5%. One toxic death (1.1%) due to sepsis was noted.
Conclusion
The combination of bortezomib, doxorubicin and dexamethasone (PAD) is well tolerated and induced clinically signifiant responses and prolonged remission duration in patients with relapsed and refractory MM.
Session topic: E-poster
{{ help_message }}
{{filter}}